Northwestern University Feinberg School of Medicine
Pablo Penaloza Lab
Skip to main content

Publications

Learn more about the work that we do in the Penaloza Laboratory through our recent publications.

  1. Richner J, Class J, Simons L, Lorenzo-Redondo R, Cooper L, Dangi T, Penaloza-MacMaster P, Ozer E, Rong L, Hultquist J  SARS-CoV-2 Bottlenecks and Tissue-Specific Adaptation in the Central Nervous System.  Res Sq  2023 Sep 11;. pii:rs.3.rs-3220157
  2. Visvabharathy L, Hanson BA, Orban ZS, Lim PH, Palacio NM, Jimenez M, Clark JR, Graham EL, Liotta EM, Tachas G  et al.  Corrigendum: Neuro-PASC is characterized by enhanced CD4+ and diminished CD8+ T cell responses to SARSCoV-2 Nucleocapsid protein.  Front Immunol  2023;14:1275925. pii:1275925
  3. Visvabharathy L, Hanson BA, Orban ZS, Lim PH, Palacio NM, Jimenez M, Clark JR, Graham EL, Liotta EM, Tachas G  et al.  Neuro-PASC is characterized by enhanced CD4+ and diminished CD8+ T cell responses to SARS-CoV-2 Nucleocapsid protein.  Front Immunol  2023;14:1155770. pii:1155770
  4. Visvabharathy L, Zhu C, Orban ZS, Yarnoff K, Palacio N, Jimenez M, Lim PH, Penaloza-MacMaster P, Koralnik IJ  Autoantibody production is enhanced after mild SARS-CoV-2 infection despite vaccination in individuals with and without long COVID.  medRxiv  2023 Apr 12;. pii:2023.04.07.23288243
  5. Cable J, Sun J, Cheon IS, Vaughan AE, Castro IA, Stein SR, López CB, Gostic KM, Openshaw PJM, Ellebedy AH  et al.  Respiratory viruses: New frontiers-a Keystone Symposia report.  Ann N Y Acad Sci  2023 Apr;1522(1):60-73. doi:10.1111/nyas.14958
  6. Dangi T, Sanchez S, Lew MH, Awakoaiye B, Visvabharathy L, Richner JM, Koralnik IJ, Penaloza-MacMaster P  Pre-existing immunity modulates responses to mRNA boosters.  Cell Rep  2023 Mar 28;42(3):112167. doi:10.1016/j.celrep.2023.112167
  7. Pan T, Cao G, Tang E, Zhao Y, Penaloza-MacMaster P, Fang Y, Huang J  A single-cell atlas reveals shared and distinct immune responses and metabolic profiles in SARS-CoV-2 and HIV-1 infections.  Front Genet  2023;14:1105673. pii:1105673
  8. Dangi T, Sanchez S, Class J, Richner M, Visvabharathy L, Chung YR, Bentley K, Stanton RJ, Koralnik IJ, Richner JM  et al.  Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody.  J Clin Invest  2022 Dec 01;132(23). pii:e162282
  9. Visvabharathy L, Hanson BA, Orban ZS, Lim PH, Palacio NM, Jimenez M, Clark JR, Graham EL, Liotta EM, Tachas G  et al.  T cell responses to SARS-CoV-2 in people with and without neurologic symptoms of long COVID.  medRxiv  2022 Oct 21;. pii:2021.08.08.21261763
  10. Chung YR, Dangi T, Palacio N, Sanchez S, Penaloza-MacMaster P  Adoptive B cell therapy for chronic viral infection.  Front Immunol  2022;13:908707. pii:908707
  11. Dangi T, Sanchez S, Lew MH, Visvabharathy L, Richner J, Koralnik IJ, Penaloza-MacMaster P  Pre-existing immunity modulates responses to mRNA boosters.  bioRxiv  2022 Jun 28;. pii:2022.06.27.497248
  12. Pan T, Cao G, Tang E, Zhao Y, Penaloza-MacMaster P, Fang Y, Huang J  A single-cell atlas reveals shared and distinct immune responses and metabolism during SARS-CoV-2 and HIV-1 infections.  bioRxiv  2022 Jan 11;. pii:2022.01.10.475725
  13. Cai X, Chen M, Prominski A, Lin Y, Ankenbruck N, Rosenberg J, Nguyen M, Shi J, Tomatsidou A, Randall G  et al.  A Multifunctional Neutralizing Antibody-Conjugated Nanoparticle Inhibits and Inactivates SARS-CoV-2.  Adv Sci (Weinh)  2022 Jan;9(2):e2103240. pii:2103240
  14. Dangi T, Palacio N, Sanchez S, Park M, Class J, Visvabharathy L, Ciucci T, Koralnik IJ, Richner JM, Penaloza-MacMaster P  Cross-protective immunity following coronavirus vaccination and coronavirus infection.  J Clin Invest  2021 Dec 15;131(24). pii:e151969
  15. Neef T, Ifergan I, Beddow S, Penaloza-MacMaster P, Haskins K, Shea LD, Podojil JR, Miller SD  Tolerance Induced by Antigen-Loaded PLG Nanoparticles Affects the Phenotype and Trafficking of Transgenic CD4+ and CD8+ T Cells.  Cells  2021 Dec 07;10(12). pii:3445
  16. Sanchez S, Palacio N, Dangi T, Ciucci T, Penaloza-MacMaster P  Fractionating a COVID-19 Ad5-vectored vaccine improves virus-specific immunity.  Sci Immunol  2021 Dec 03;6(66):eabi8635. doi:10.1126/sciimmunol.abi8635
  17. Dangi T, Class J, Palacio N, Richner JM, Penaloza MacMaster P  Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2.  Cell Rep  2021 Sep 07;36(10):109664. doi:10.1016/j.celrep.2021.109664
  18. Chen M, Rosenberg J, Cai X, Lee ACH, Shi J, Nguyen M, Wignakumar T, Mirle V, Edobor AJ, Fung J  et al.  Nanotraps for the containment and clearance of SARS-CoV-2.  Matter  2021 Jun 02;4(6):2059-2082. doi:10.1016/j.matt.2021.04.005
  19. Sanchez S, Palacio N, Dangi T, Ciucci T, Penaloza-MacMaster P  Limiting the priming dose of a SARS CoV-2 vaccine improves virus-specific immunity.  bioRxiv  2021 Apr 01;. pii:2021.03.31.437931
  20. Palacio N, Dangi T, Chung YR, Wang Y, Loredo-Varela JL, Zhang Z, Penaloza-MacMaster P  Early type I IFN blockade improves the efficacy of viral vaccines.  J Exp Med  2020 Dec 07;217(12). pii:e20191220
  21. Cai X, Prominski A, Lin Y, Ankenbruck N, Rosenberg J, Chen M, Shi J, Chang EB, Penaloza-MacMaster P, Tian B  et al.  A Neutralizing Antibody-Conjugated Photothermal Nanoparticle Captures and Inactivates SARS-CoV-2.  bioRxiv  2020 Nov 30;. pii:2020.11.30.404624
  22. Dangi T, Chung YR, Palacio N, Penaloza-MacMaster P  Interrogating Adaptive Immunity Using LCMV.  Curr Protoc Immunol  2020 Sep;130(1):e99. doi:10.1002/cpim.99
  23. Wang Y, Chung YR, Eitzinger S, Palacio N, Gregory S, Bhattacharyya M, Penaloza-MacMaster P  TLR4 signaling improves PD-1 blockade therapy during chronic viral infection.  PLoS Pathog  2019 Feb;15(2):e1007583. pii:e1007583
  24. Bhattacharyya M, Whitney JB, Seaman M, Barouch DH, Penaloza-MacMaster P  T-cell subset differentiation and antibody responses following antiretroviral therapy during simian immunodeficiency virus infection.  Immunology  2018 Dec;155(4):458-466. doi:10.1111/imm.12985
  25. Badamchi-Zadeh A, Moynihan KD, Larocca RA, Aid M, Provine NM, Iampietro MJ, Kinnear E, Penaloza-MacMaster P, Abbink P, Blass E  et al.  Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy.  J Immunol  2018 Nov 01;201(9):2744-2752. doi:10.4049/jimmunol.1800885
  26. Blass E, Aid M, Martinot AJ, Larocca RA, Kang ZH, Badamchi-Zadeh A, Penaloza-MacMaster P, Reeves RK, Barouch DH  Adenovirus Vector Vaccination Impacts NK Cell Rheostat Function following Lymphocytic Choriomeningitis Virus Infection.  J Virol  2018 Jun 01;92(11). pii:e02103-17
  27. Bhattacharyya M, Penaloza-MacMaster P  Dynamics of Lymphocyte Reconstitution After Hematopoietic Transplantation During Chronic Lymphocytic Choriomeningitis Virus Infection.  AIDS Res Hum Retroviruses  2018 May;34(5):430-438. doi:10.1089/AID.2017.0251
  28. Xu D, Robinson AP, Ishii T, Duncan DS, Alden TD, Goings GE, Ifergan I, Podojil JR, Penaloza-MacMaster P, Kearney JA  et al.  Peripherally derived T regulatory and γδ T cells have opposing roles in the pathogenesis of intractable pediatric epilepsy.  J Exp Med  2018 Apr 02;215(4):1169-1186. doi:10.1084/jem.20171285
  29. Nakashima H, Alayo QA, Penaloza-MacMaster P, Freeman GJ, Kuchroo VK, Reardon DA, Fernandez S, Caligiuri M, Chiocca EA  Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells.  Sci Rep  2018 Jan 09;8(1):208. pii:208
  30. Alayo QA, Provine NM, Penaloza-MacMaster P  Novel Concepts for HIV Vaccine Vector Design.  mSphere  2017;2(6). pii:e00415-17
  31. Bhattacharyya M, Madden P, Henning N, Gregory S, Aid M, Martinot AJ, Barouch DH, Penaloza-MacMaster P  Regulation of CD4 T cells and their effects on immunopathological inflammation following viral infection.  Immunology  2017 Oct;152(2):328-343. doi:10.1111/imm.12771
  32. Bhattacharyya M, Penaloza-MacMaster P  T regulatory cells are critical for the maintenance, anamnestic expansion and protection elicited by vaccine-induced CD8 T cells.  Immunology  2017 Jul;151(3):340-348. doi:10.1111/imm.12734
  33. Penaloza-MacMaster P  CD8 T-cell regulation by T regulatory cells and the programmed cell death protein 1 pathway.  Immunology  2017 Jun;151(2):146-153. doi:10.1111/imm.12739
  34. Penaloza MacMaster P, Shields JL, Alayo QA, Cabral C, Jimenez J, Mondesir J, Chandrashekar A, Cabral JM, Lim M, Iampietro MJ  et al.  Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens.  Vaccine  2017 Jan 03;35(1):1-9. doi:10.1016/j.vaccine.2016.11.063
  35. Larocca RA, Provine NM, Aid M, Iampietro MJ, Borducchi EN, Badamchi-Zadeh A, Abbink P, Ng'ang'a D, Bricault CA, Blass E  et al.  Adenovirus serotype 5 vaccine vectors trigger IL-27-dependent inhibitory CD4+ T cell responses that impair CD8+ T cell function.  Sci Immunol  2016 Nov;1(5). pii:eaaf7643
  36. Penaloza-MacMaster P, Alayo QA, Ra J, Provine NM, Larocca R, Lee B, Barouch DH  Inhibitory receptor expression on memory CD8 T cells following Ad vector immunization.  Vaccine  2016 Sep 22;34(41):4955-4963. doi:10.1016/j.vaccine.2016.08.048
  37. Provine NM, Larocca RA, Aid M, Penaloza-MacMaster P, Badamchi-Zadeh A, Borducchi EN, Yates KB, Abbink P, Kirilova M, Ng'ang'a D  et al.  Immediate Dysfunction of Vaccine-Elicited CD8+ T Cells Primed in the Absence of CD4+ T Cells.  J Immunol  2016 Sep 01;197(5):1809-22. doi:10.4049/jimmunol.1600591
  38. Provine NM, Badamchi-Zadeh A, Bricault CA, Penaloza-MacMaster P, Larocca RA, Borducchi EN, Seaman MS, Barouch DH  Transient CD4+ T Cell Depletion Results in Delayed Development of Functional Vaccine-Elicited Antibody Responses.  J Virol  2016 May;90(9):4278-4288. doi:10.1128/JVI.00039-16
  39. Penaloza-MacMaster P, Provine NM, Blass E, Barouch DH  CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells.  J Immunol  2015 Aug 01;195(3):1054-63. doi:10.4049/jimmunol.1403237
  40. Rodríguez-Rodríguez N, Apostolidis SA, Penaloza-MacMaster P, Martín Villa JM, Barouch DH, Tsokos GC, Crispín JC  Programmed cell death 1 and Helios distinguish TCR-αβ+ double-negative (CD4-CD8-) T cells that derive from self-reactive CD8 T cells.  J Immunol  2015 May 01;194(9):4207-14. doi:10.4049/jimmunol.1402775
  41. Penaloza-MacMaster P, Barber DL, Wherry EJ, Provine NM, Teigler JE, Parenteau L, Blackmore S, Borducchi EN, Larocca RA, Yates KB  et al.  Vaccine-elicited CD4 T cells induce immunopathology after chronic LCMV infection.  Science  2015 Jan 16;347(6219):278-82. doi:10.1126/science.aaa2148
  42. Penaloza-MacMaster P, Kamphorst AO, Wieland A, Araki K, Iyer SS, West EE, O'Mara L, Yang S, Konieczny BT, Sharpe AH  et al.  Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection.  J Exp Med  2014 Aug 25;211(9):1905-18. doi:10.1084/jem.20132577
  43. Whitney JB, Hill AL, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M, Parenteau L, Cabral C, Shields J, Blackmore S  et al.  Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys.  Nature  2014 Aug 07;512(7512):74-7. doi:10.1038/nature13594
  44. Teigler JE, Penaloza-MacMaster P, Obeng R, Provine NM, Larocca RA, Borducchi EN, Barouch DH  Hexon hypervariable region-modified adenovirus type 5 (Ad5) vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectors.  Clin Vaccine Immunol  2014 Aug;21(8):1137-44. doi:10.1128/CVI.00207-14
  45. Provine NM, Larocca RA, Penaloza-MacMaster P, Borducchi EN, McNally A, Parenteau LR, Kaufman DR, Barouch DH  Longitudinal requirement for CD4+ T cell help for adenovirus vector-elicited CD8+ T cell responses.  J Immunol  2014 Jun 01;192(11):5214-25. doi:10.4049/jimmunol.1302806
  46. Penaloza-MacMaster P, Teigler JE, Obeng RC, Kang ZH, Provine NM, Parenteau L, Blackmore S, Ra J, Borducchi EN, Barouch DH  Augmented replicative capacity of the boosting antigen improves the protective efficacy of heterologous prime-boost vaccine regimens.  J Virol  2014 Jun;88(11):6243-54. doi:10.1128/JVI.00406-14
  47. Iyer SS, Latner DR, Zilliox MJ, McCausland M, Akondy RS, Penaloza-Macmaster P, Hale JS, Ye L, Mohammed AU, Yamaguchi T  et al.  Identification of novel markers for mouse CD4(+) T follicular helper cells.  Eur J Immunol  2013 Dec;43(12):3219-32. doi:10.1002/eji.201343469
  48. West EE, Jin HT, Rasheed AU, Penaloza-Macmaster P, Ha SJ, Tan WG, Youngblood B, Freeman GJ, Smith KA, Ahmed R  PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells.  J Clin Invest  2013 Jun;123(6):2604-15. doi:10.1172/JCI67008
  49. Tan WG, Jin HT, West EE, Penaloza-MacMaster P, Wieland A, Zilliox MJ, McElrath MJ, Barouch DH, Ahmed R  Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors.  J Virol  2013 Feb;87(3):1359-72. doi:10.1128/JVI.02055-12
  50. Penaloza-MacMaster P, Provine NM, Ra J, Borducchi EN, McNally A, Simmons NL, Iampietro MJ, Barouch DH  Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors.  J Virol  2013 Feb;87(3):1373-84. doi:10.1128/JVI.02058-12